Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Ponzone
Riccardo
R
Biglia
Nicoletta
N
Sismondi
Piero
P
D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D017374:Paroxetine / Q000008:administration & dosage* / Q000494:pharmacology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D013629:Tamoxifen / Q000008:administration & dosage* / Q000097:blood* / Q000493:pharmacokinetics
D018687:Antidepressive Agents, Second-Generation; D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D020847:Estrogen Receptor Modulators; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013629:Tamoxifen